TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31794478
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment (control)
Study: 29040598
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 1 g twice a day)
Study: 23173821
Drug: Adalimumab (160/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter)
Study: 23173821
Drug: Adalimumab (160/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter) in patients using corticosteroids at baseline (N=90)
Study: 11505349
Drug: 17beta-estradiol, 2mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol, 2mg, given orally twice in 14 hours before the operation
Study: 9305559
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion at 6.0 +/- 0.4 micrograms.kg-1.min-1 in young adults
Study: 9305559
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion at 4.3 +/- 0.3 micrograms.kg-1.min-1 in elderly patients
Study: 9305559
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion in patients with low plasma cholinesterase activity
Study: 9305559
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion titrated to maintain 95 +/- 4% twitch depression
Study: 9305559
Drug: Mivacurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium infusion with or without antagonism
Study: 8280653
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MAP) 1g/day i.m. 5 days/week for 4 weeks and then 500 mg twice a week
Study: 8280653
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/day orally
Study: 27103382
Drug: Anticoagulant users
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant users (n=32)
Study: 27103382
Drug: Baseline anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline anticoagulant use
Study: 27103382
Drug: Anticoagulant use
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant use at any time during the study
Study: 26138109
Drug: Dorsal onlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal onlay buccal mucosal graft urethroplasty
Study: 23931150
Drug: Dorsal inlay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal inlay buccal mucosal graft urethroplasty
Study: 17351767
Drug: GABAB receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABAB receptor agonist baclofen
Study: 11428734
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler (400 microg, once daily)
Study: 7906757
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment (nicoumalone or phenprocoumon)
Study: 6179410
Drug: High-protein supplements
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein supplements
Study: 6179410
Drug: Balanced protein-calorie
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced protein-calorie supplements
Study: 11451713
Drug: Nutritional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional treatment
Study: 22945298
Drug: rhIGF1 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF1 (15 μg/kg per day for 1 month and 30 μg/kg per day for 5 months)
Study: 12585000
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray (400 micrograms daily for 6 weeks for isolated rhinitis and 6 months for associated forms)
Study: 30769263
Drug: Integrated Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive Behavioral Therapy (CBT/Integrated) - 15 individual sessions including motivational therapy, coping skills training, relapse prevention for SUD, and ADHD skills training
Study: 30769263
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy directed at SUD only (CBT/SUD) - 10 individual SUD treatment sessions
Study: 30769263
Drug: Integrated Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive Behavioral Therapy (CBT/Integrated)
Study: 30769263
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy directed at SUD only (CBT/SUD)
Study: 26271344
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g metformin twice daily
Study: 21737373
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of rhLFA3‐IgFP (15 mg/week)
Study: 21737373
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of blank dummy methotrexate (7.5 mg/week)
Study: 21737373
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received oral methotrexate (7.5 mg/week) and intramuscular injection of blank dummy rhLFA3‐IgFP (15 mg/week)
Study: 11519634
Drug: Diazepam 0
Normalized name: diazepam 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0 mg (placebo)
Study: 7918915
Drug: Gore‐Tex membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gore‐Tex membrane treatment
Study: 7918915
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no Gore‐Tex membrane)
Study: 28716684
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection (1–2 mL; 15 orbits)
Study: 28716684
Drug: Medial canthal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial canthal peribulbar injection (2–8 mL; PB-1; 16 orbits)
Study: 28716684
Drug: Dorsomedial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsomedial and ventrolateral peribulbar injections (each 1–4 mL; PB-2; 16 orbits)
Study: 26337247
Drug: Vibration device
Normalized name: VIBRATING DEVICE,CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration device (80 Hz, 5 minutes daily for 6 months)
Study: 23222369
Drug: MRC Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRC Chemotherapy + ATRA
Study: 3542850
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg b.i.d.
Study: 3542850
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg b.i.d.
Study: 30358711
Drug: CYC‐PERT (cyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYC‐PERT (cyclic combination therapy adding progesterone to estrogen)
Study: 30358711
Drug: CC‐PERT (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐PERT (continuous combined estrogen progestin therapy)
Study: 19775763
Drug: Allopurinol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (loading dose 400 mg followed by 100 mg for 1 month)
Study: 12779015
Drug: Adjuvant autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant autologous tumour cell-lysate vaccine (6 applications at 4-week intervals after radical nephrectomy)
Study: 12779015
Drug: Adjuvant autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant autologous tumour cell-lysate vaccine
Study: 10580024
Drug: 6-mercaptopurine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine (75 mg/m2) given for 2.5 years, interrupted every 6 weeks for treatment with either high-dose methotrexate or teniposide plus cytarabine.
Study: 10580024
Drug: 6-mercaptopurine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine (75 mg/m2)
Study: 8904679
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodothyronine (T3) administered as a loading dose at various points during surgery and followed by continuous infusion.
Study: 1991426
Drug: Nd‐YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd‐YAG laser phototherapy and CO2 laser treatment (Group A)
Study: 6371293
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg tobramycin (TOB) administered twice a day for 10 days
Study: 6371293
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tobramycin (TOB) administered three times a day for 10 days
Study: 6371293
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg tobramycin (TOB) for bacterial pneumonia and lung abscess
Study: 6371293
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tobramycin (TOB) for bacterial pneumonia and lung abscess
Study: 6371293
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg tobramycin (TOB) against chronic RTI
Study: 6371293
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tobramycin (TOB) against chronic RTI
Study: 6371293
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg tobramycin (TOB) against chronic bronchitis
Study: 6371293
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tobramycin (TOB) against chronic bronchitis
Study: 29347988
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg, Circadin®)
Study: 25219475
Drug: Ultrasound-guided needling
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided needling with subacromial corticosteroid injection
Study: 22933480
Drug: Interactive Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Voice Response (IVR) administration of PHQ-9
Study: 22933480
Drug: Paper-and-pencil administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-pencil administration of PHQ-9
Study: 21298836
Drug: 1550 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1550 nm Erbium fiber laser treatment, once a week for 8 successive treatments
Study: 16244020
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic (20 mL of 2% lidocaine) administered through the epidural needle before catheter insertion
Study: 7491367
Drug: Ginkobene (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkobene (3 x 40 mg daily for 57 days)
Study: 16923090
Drug: GIK (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (50% dextrose in 500 ml of water; regular insulin, 125 IU; potassium, 80 mmol) at 0.75 ml/kg/h
Study: 7712668
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (regimen A): 60 mg/kg intravenous foscarnet and 3.75 mg/kg ganciclovir
Study: 7712668
Drug: Daily alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily alternating therapy (regimen B): 120 mg/kg foscarnet and 6 mg/kg ganciclovir
Study: 2664883
Drug: L‐5‐hydroxytryptophan (L‐5HTP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐5‐hydroxytryptophan (L‐5HTP)
Study: 31991513
Drug: High-dose nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nitroglycerin (5 µg·kg‐1 ·min‐1)
Study: 31991513
Drug: Low-dose nitroglycerin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nitroglycerin (1 µg·kg‐1 ·min‐1)
Study: 31093677
Drug: GM1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 (80 mg, day -1 to day 2)
Study: 28355756
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg intravenously before induction and followed by 2.0 mg·kg(‐1)·h(‐1) to the end of surgery
Study: 23529800
Drug: Minodronate 1
Normalized name: Minodronate
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronate 1 mg once a day for 24 months
Study: 21253777
Drug: Cinacalcet treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet treatment for 12 months
Study: 16165158
Drug: Fluoxetine (20-60mg/day)
Normalized name: fluoxetine 60 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (20-60mg/day)
Study: 15529377
Drug: MTX-3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-3 mg/kg infliximab
Study: 15529377
Drug: MTX-6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-6 mg/kg infliximab
Study: 11527433
Drug: Verification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verification of properties using local representation (e.g., verifying 'mane' for PONY after verifying 'mane' for HORSE)
Study: 11527433
Drug: Verification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verification of properties using global representation (e.g., verifying 'mane' for PONY after verifying 'mane' for LION)
Study: 9692703
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 4 weeks + clarithromycin 500 mg b.d. (Group A)
Study: 9692703
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 4 weeks + clarithromycin 500 mg t.d.s. (Group B)
Study: 29096681
Drug: SlowMo intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SlowMo intervention added to treatment as usual (TAU)
Study: 26237622
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg) therapy, 50 mg/kg bolus immediately after induction of anesthesia followed by another 50 mg/kg infusion over 3 hours (total dose, 100 mg/kg)
Study: 26237622
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg) therapy
Study: 15453909
Drug: Psyllium hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium hydrophilic mucilloid (12.7 g daily) taken in the morning
Study: 15453909
Drug: Psyllium hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium hydrophilic mucilloid (12.7 g daily) taken in the evening
Study: 15453909
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no psyllium administration)
Study: 9640160
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate 6 mg kg‐1 h‐1
Study: 7856286
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (captopril 3 x 12.5 mg, lisinopril 1 x 10 mg, enalapril 1 x 10 mg)
Study: 7856286
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (captopril, lisinopril, enalapril)
Study: 7856286
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors with acetylsalicylic acid
Study: 2530717
Drug: 1‐Ar (1-inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐Ar (1-inch needle injection in the arm)
Study: 2530717
Drug: 1‐Bu (1-inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐Bu (1-inch needle injection in the buttock)
Study: 2530717
Drug: 2‐Bu (2-inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐Bu (2-inch needle injection in the buttock)
Study: 30211826
Drug: CNI-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-based treatment
Study: 28732433
Drug: Salt therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt therapy (staying in the salt room for one hour, three times a week for 3 consecutive weeks)
Study: 17467230
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention (weekly for 4 months, followed by monthly sessions for 8 months)
Study: 15733403
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine 2 mg, bid, for 2‐4 weeks
Study: 11738122
Drug: Antihypertensive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive and lipid-lowering therapy
Study: 8147352
Drug: Antimycobacterial drugs
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimycobacterial drugs (ethambutol, clofazimine, dapsone, and 1-day dose of rifampicin)
Study: 3347325
Drug: HCT dosage
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT dosage doubled after 1 month
Study: 27768509
Drug: Monthly payment
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly payment willingness to pay (WTP)
Study: 25812483
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (weekly or bi-weekly assessments via texts)
Study: 23672202
Drug: Irsogladine 4
Normalized name: irsogladine
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine 4 mg daily for 14 days with diclofenac sodium 75 mg
Study: 23672202
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg daily for 14 days with diclofenac sodium 75 mg
Study: 11429342
Drug: ropivacaine 0.08%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.04 microg.kg(‐1).h(‐1) (Group RC1)
Study: 11429342
Drug: ropivacaine 0.08%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.08 microg.kg(‐1).h(‐1) (Group RC2)
Study: 11429342
Drug: ropivacaine 0.08%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.08% 0.16 mg.kg(‐1).h(‐1) plus clonidine 0.12 microg.kg(‐1).h(‐1) (Group RC3)
Study: 11429342
Drug: ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.1% 0.2 mg.kg(‐1).h(‐1) (Group R)
Study: 9589248
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel 100 micrograms/g
Study: 2532741
Drug: Intravenous 99‐126
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 99‐126 atrial natriuretic factor (ANF) infusion
Study: 20434097
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 15 mg of hyperbaric ropivacaine plus 25 microg of fentanyl
Study: 20434097
Drug: Low-dose spinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spinal anesthesia with 10 mg of hyperbaric ropivacaine plus 25 microg of fentanyl
Study: 20434097
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 112.5 mg of ropivacaine plus 25 microg of fentanyl
Study: 2318518
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg once or twice daily or 50 mg once or twice daily)
Study: 2318518
Drug: Hydralazine, methyldopa,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine, methyldopa, metoprolol, or reserpine (added to diuretic therapy for nonresponders)
Study: 29474306
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab combined with oral DHA supplementation (1,050 mg/day)
Study: 28285845
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg once daily for 14-18 weeks
Study: 22859317
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) protocol: systemic NAC infusion (30 mg/kg) 1 hour before liver procurement and locoregional NAC infusion (300 mg through the portal vein) just before cross-clamping
Study: 17707639
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy +/‐ radiotherapy followed by delayed surgical resection
Study: 17707639
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with surgical resection for metastatic disease
Study: 17707639
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of ifosfamide and doxorubicin in chemotherapy regimes
Study: 15236398
Drug: Levodopa (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100mg daily for 5 days)
Study: 11878738
Drug: Epidural methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural methylprednisolone (MP) 1 mg kg(‐1) followed by continuous infusion of MP 1.5 mg kg(‐1) for 48 hours
Study: 11878738
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline as a bolus injection and continuous epidural infusion (P group)
Study: 7819468
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) administered to reduce mean arterial pressure to 50 mmHg